VIVUS Inc. (VVUS)

4.29
NASDAQ : Health Technology
Prev Close 4.17
Day Low/High 4.14 / 4.31
52 Wk Low/High 2.15 / 5.78
Avg Volume 115.60K
Exchange NASDAQ
Shares Outstanding 10.64M
Market Cap 44.38M
EPS -3.50
P/E Ratio N/A
Div & Yield N.A. (N.A)
Adobe, Orexigen: After-Hours Trading

Adobe, Orexigen: After-Hours Trading

The big movers after Tuesday's closing bell included Adobe Systems, Orexigen Therapeutics, and Oracle.

Orexigen Resurrects Rejected Obesity Drug

Orexigen Resurrects Rejected Obesity Drug

An agreement with FDA for a shorter safety study allows Orexigen to restart development of its obesity drug Contrave.

5 Stocks Poised for Breakouts

5 Stocks Poised for Breakouts

These stocks look poised to break out and trade higher from current prices.

Biotech Stock Mailbag: Vivus

Biotech Stock Mailbag: Vivus

Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.

Biotech Stock Live Chat

Biotech Stock Live Chat

TheStreet's biotech columnist Adam Feuerstein is holding a live, interactive discussion about biotech stock investing.

Biotech Stock Mailbag: Sangamo Biosciences

Biotech Stock Mailbag: Sangamo Biosciences

Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.

Vivus Puts Obesity Drug On A Diet

Vivus Puts Obesity Drug On A Diet

Vivus wants to restrict use of Qnexa in order to get the delayed weight-loss drug approved, but that also means lower sales.

Chesapeake, Vivus: After-Hours Trading

Chesapeake, Vivus: After-Hours Trading

Shares of Chesapeake Energy and Vivus were active in Monday's after-hours session.

Muni Bonds, "The Next Boom", Action Alerts Plus

Muni Bonds, "The Next Boom", Action Alerts Plus

Guests include Jack Plunkett, author of "The Next Boom", Stephanie Link, director of research at TheStreet and Robert DiMella, portfolio manager for the MainStay Tax Free Bond Fund

Vivus Offers One-Sided Story of Qnexa

Vivus Offers One-Sided Story of Qnexa

Vivus reports positive heart-risk data on its weight-loss drug Qnexa without disclosing potential negatives.

Vivus, Orexigen: Small-Cap Winners

Vivus, Orexigen: Small-Cap Winners

TheStreet presents a rundown of the winners in the small-cap space during the day's trading.

Biotech Stock Mailbag: Cadence Pharma

Biotech Stock Mailbag: Cadence Pharma

Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.

Biotech Stock Mailbag: Protalix BioTherapeutics

Biotech Stock Mailbag: Protalix BioTherapeutics

Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.

Obesity Drugs: The Road to Perdition

Obesity Drugs: The Road to Perdition

Obesity drugs are dead following FDA's rejection of Orexigen Tuesday, which also spells doom for Vivus and Arena Pharma.

Orexigen: 'Bad' Rejection of Obesity Drug

Orexigen: 'Bad' Rejection of Obesity Drug

FDA reject Orexigen's weight-loss drug Contrave and tells the company that additional clinical data will be needed.

Arena Pharma: Weight-Loss Drug Woes

Arena Pharma: Weight-Loss Drug Woes

FDA asks Arena for more studies and data to ensure the safety of its weight-loss drug, jeopardizing approval chances.

Biotech Stock Mailbag: Orexigen Therapeutics

Biotech Stock Mailbag: Orexigen Therapeutics

Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.

Vivus Obesity Drug Hit With New Safety Concerns

Vivus Obesity Drug Hit With New Safety Concerns

FDA has asked Vivus to collect new safety data on cleft lips, possibly delaying Qnexa's resubmission.

Arena: Long, Hard 'Path' to Obesity Drug Approval

Arena: Long, Hard 'Path' to Obesity Drug Approval

Arena must spend next year conducting new studies before re-filing its weight-loss drug lorcaserin with FDA.

Biotech Sector Weekly Rewind

Biotech Sector Weekly Rewind

Adam Feuerstein's take on the biotech sector's hits and misses during the week ended Dec. 10, 2010.

Biotech Stock Mailbag: Orexigen and Vivus

Biotech Stock Mailbag: Orexigen and Vivus

Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.

Diet Drug Rally: Orexigen, Vivus, Arena

Diet Drug Rally: Orexigen, Vivus, Arena

An FDA advisory panel approves the first new diet drug in ten years, Orexigen Therapeutics' Contrave, and shares of diet drug makers rally.

Home Depot, Costco: Premarket Trading

Home Depot, Costco: Premarket Trading

Home Depot said Wednesday it expects fiscal-year sales to rise 2.3% with earnings from continuing operations up 27%.

Men's Wearhouse, Orexigen: After-Hours Trades

Men's Wearhouse, Orexigen: After-Hours Trades

Men's Wearhouse, Netflix, Orexigen, Vivus and Texas Instruments were big movers in extended trading on Tuesday.

Orexigen Therapeutics: FDA Panel Live Blog

Orexigen Therapeutics: FDA Panel Live Blog

Orexigen brings its weight-loss drug Contrave skin in front of an FDA advisory panel today.

Orexigen: Predicting Tuesday's FDA Panel

Orexigen: Predicting Tuesday's FDA Panel

An analysis of the experts sitting on Tuesday's Orexigen FDA panel gives some insight into the fate of the company's weight-loss drug Contrave.

Orexigen: Contrave FDA Panel Preview

Orexigen: Contrave FDA Panel Preview

What to expect when Contrave brings its weight-loss drug Contrave in front of an FDA advisory panel next week.

Biotech Stock Mailbag: Theratechnologies

Biotech Stock Mailbag: Theratechnologies

Biotech columnist Adam Feuerstein answers readers' questions about drug and health care-related firms.

Arena: 'Marginal' Obesity Drug Now Unsafe?

Arena: 'Marginal' Obesity Drug Now Unsafe?

New study results show lorcaserin doesn't help diabetics lose much weight and heart safety questions emerge.

TheStreet Quant Rating: D (Sell)